Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 2
2001 2
2002 3
2003 6
2004 9
2005 10
2006 20
2007 18
2008 18
2009 22
2010 28
2011 35
2012 37
2013 43
2014 61
2015 76
2016 88
2017 97
2018 108
2019 121
2020 161
2021 182
2022 159
2023 158
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

1,318 results

Results by year

Filters applied: . Clear all
Page 1
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Ng SC, et al. Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16. Lancet. 2017. PMID: 29050646 Review.
The highest reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's disease 322 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's disease 319 per 100 000 in Canada). ...Since 19 …
The highest reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's disease 322 per 100 000 …
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Lasa JS, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29. Lancet Gastroenterol Hepatol. 2022. PMID: 34856198
BACKGROUND: There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis …
BACKGROUND: There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the rela …
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. Turner D, et al. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. Gastroenterology. 2021. PMID: 33359090
Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth. ...
Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as …
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. Singh S, et al. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13. Clin Gastroenterol Hepatol. 2020. PMID: 31945470 Free PMC article. Review.
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naive) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moderate to severely active ulcerative colitis in a systematic review and …
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naive) and second-line (prior exposure to tumor …
Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
Nielsen DL, Juhl CB, Chen IM, Kellermann L, Nielsen OH. Nielsen DL, et al. Cancer Treat Rev. 2022 Sep;109:102440. doi: 10.1016/j.ctrv.2022.102440. Epub 2022 Jul 26. Cancer Treat Rev. 2022. PMID: 35917654 Free article. Review.
Key inclusion criteria were for Study I) phase I-IV trials, and data on diarrhea and/or colitis; for Study II) studies describing histopathologic and endoscopic findings and/or biologic treatment for ICI-induced colitis. ...The incidence of all-grade diarrhea follow …
Key inclusion criteria were for Study I) phase I-IV trials, and data on diarrhea and/or colitis; for Study II) studies describing his …
Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.
Panaccione R, Lee WJ, Clark R, Kligys K, Campden RI, Grieve S, Raine T. Panaccione R, et al. Adv Ther. 2023 May;40(5):2051-2081. doi: 10.1007/s12325-023-02457-6. Epub 2023 Mar 17. Adv Ther. 2023. PMID: 36930430 Free PMC article. Review.
INTRODUCTION: Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in CD and U …
INTRODUCTION: Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn's disease (CD) and ul …
Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review.
Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, Wilson DC, Cameron F, Henderson P, Kotze PG, Bhatti J, Fang V, Gerber S, Guay E, Kotteduwa Jayawarden S, Kadota L, Maldonado D F, Osei JA, Sandarage R, Stanton A, Wan M; InsightScope Pediatric IBD Epidemiology Group; Benchimol EI. Kuenzig ME, et al. Gastroenterology. 2022 Apr;162(4):1147-1159.e4. doi: 10.1053/j.gastro.2021.12.282. Epub 2022 Jan 5. Gastroenterology. 2022. PMID: 34995526 Free article.
METHODS: We systematically reviewed studies indexed in MEDLINE, EMBASE, Airiti Library, and SciELO from January 2010 to February 2020 to identify population-based studies reporting the incidence and/or prevalence of IBD, Crohn's disease, ulcerative colitis, and/or IBD-uncl …
METHODS: We systematically reviewed studies indexed in MEDLINE, EMBASE, Airiti Library, and SciELO from January 2010 to February 2020 to ide …
Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses.
Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen AA, Holroyd-Leduc J, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group; Balderramo D, Chong VH, Juliao-Baños F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwaijri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M. Buie MJ, et al. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2211-2221. doi: 10.1016/j.cgh.2022.06.030. Epub 2022 Jul 19. Clin Gastroenterol Hepatol. 2023. PMID: 35863682 Free article. Review.
METHODS: We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn's disease (CD), or ulcerative colitis (UC) in the 21st century. Log-linear models were used to calculate the average annual percentage change …
METHODS: We systematically reviewed Medline and Embase for population-based studies reporting hospitalization rates for IBD, Crohn's disease …
Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.
Steenholdt C, Dige Ovesen P, Brynskov J, Benedict Seidelin J. Steenholdt C, et al. J Crohns Colitis. 2023 Aug 21;17(8):1354-1363. doi: 10.1093/ecco-jcc/jjad036. J Crohns Colitis. 2023. PMID: 36860164
BACKGROUND: Tofacitinib has emerged as a new potential treatment for acute severe ulcerative colitis [ASUC]. We conducted a systematic review to assess efficacy, safety and integration in ASUC algorithms. ...
BACKGROUND: Tofacitinib has emerged as a new potential treatment for acute severe ulcerative colitis [ASUC]. We conducted a systemati …
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Peyrin-Biroulet L, et al. BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1. BMC Gastroenterol. 2022. PMID: 35676620 Free PMC article.
METHODS: We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. RESULTS: We identified six eligible Crohn's disease and seven eligi …
METHODS: We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patien …
1,318 results